SALT LAKE CITY, Feb. 20, 2007 (PRIME NEWSWIRE) -- LipidViro Tech, Inc. (OTCBB:LPVT), a development-stage medical device company, announced that J. S. Latino, co-founder and Head of Research, and Linda Sharkus, Ph.D., Director, will attend the National Investment Banking Association's (NIBA) Miami Capital Conference, February 22-23, 2007, at the Wyndham Grand Bay Hotel in Miami. Mr. Latino is scheduled to make a series of presentations on February 22 and 23.
NIBA is a national association of regional and independent broker-dealer and investment banking firms that facilitates the exchange of information in matters related to corporate finance, syndication and product development, and other aspects of capital formation. NIBA conferences provide a forum for companies to discuss their businesses, strategies, and growth opportunities.
About LipidViro Tech, Inc.
LipidViro Tech, Inc. is an early-stage biotechnology company engaged in research and commercial development of d-OSAB, a multi-therapeutic device-based platform. The Company's first commercial therapeutics target Ischemic Brain Stroke and Chronic Heart Failure, two diseases with few viable treatment options, and markets exceeding $20 billion annually.
During 2007 LipidViro is scheduled to commence a 100-patient Phase IIa study treating patients who have suffered an ischemic brain stroke. d-OSAB targets the untreated stroke population estimated to exceed 94% of individuals afflicted with ischemic stroke.
Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, stroke strikes more than 1.7 million people in the U.S. and EU. Seven percent of ischemic stroke patients die within 30 days, 25% die within one year. More than 50% of surviving patients have permanent disabilities that require nursing home or other long-term care. The single approved therapeutic for ischemic brain stroke patients is tPA. Patients are only eligible for tPA during a three-hour window from time of stroke, use after three hours causes bleeding in the brain which may prove fatal. Consequently, more than 94% of stroke patients are not eligible for tPA and have no other viable treatment option.